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Objectives. Atrial arrhythmias after heart transplantation have rarely been investigated. The aim of 
this study is to assess incidence, type and predictors of atrial arrhythmias during a long-term follow-
up in a large population of heart-transplanted patients.  
Methods. Consecutive patients undergone to heart transplantation at our Centre from 1990 to 2017 
were enrolled. All documented atrial arrhythmias were systematically reviewed during a long-term 
follow-up after heart transplantation. Atrial fibrillation (AF), atrial flutter and tachycardias were 
defined according to current guidelines. 
Results. Overall, 364 patients were included and followed for 120±70 months. During the follow-
up period 108 (29.7%) patients died and 3 (0.8%) underwent re-transplantation. Sinus rhythm was 
present in 355 (97.5%) patients. Nine patients had persistent atrial arrhythmias: 8 (2.2%) presented 
atypical flutter and one (0.3%) patient AF. Paroxysmal sustained arrhythmias were detected in 42 
(11.5%) patients, always atrial flutters. At univariate analysis several echocardiographic (left 
ventricular end-diastolic diameter, TEI index, mitral and tricuspid regurgitation grade) 
hemodynamic (systolic and diastolic pulmonary pressure, capillary wedge pressure) and clinical 
(dyslipidaemia, weight, pacemaker implantation) parameters related to higher incidence of atrial 
arrhythmias.  
Conclusion. Persistent atrial arrhythmias, and most of all AF, are rare among heart transplantation 
carriers, despite substantial comorbidities resulting in significant mortality. It can be speculated that 
the lesion set provided by the surgical technique, a complete and transmural electrical isolation of 
the posterior left atrium wall, represents an effective lesion set to prevent persistent AF. 
 




• Heart transplantation creates electrical barriers, similar to surgical AF ablation. 
• Heart transplantation carriers may experience non-AF paroxysmal arrhythmias (e.g. 
incisional atrial tachycardias).  
• Persistent AF in heart transplantation carriers is extremely rare. 






Heart transplantation is considered the standard treatment for selected cases of advanced end-stage 
heart failure1. The surgical technique, originally described by Lower and Shumway is characterized 
by the surgical incision on the posterior wall of both left and right atria, resulting in a final suture 
combining the LA posterior wall and the sinus of venae cavae of the recipient with the atrial cuffs 
of the graft2. To date, little has been reported concerning incidence and predictors of atrial 
arrhythmias in the long-term of patients after heart transplantation. 
On top of this, the treatment of persistent atrial fibrillation (AF) in the general population is affected 
by poor outcome; indeed, not as good as for paroxysmal AF3. The standard catheter ablation (CA) 
approach of pulmonary vein isolation alone achieves poor results in patients with persistent AF, and 
additional substrate modification is often required to obtain satisfactory results. In fact, an ideal 
ablation set for persistent AF has not been established. Linear lesions in the left atrium (LA), 
resembling surgical maze procedure4,5, and the ablation of complex fractioned atrial electrograms6 
or rotors7 have been proposed, with promising but sometimes contrasting results.  
In this setting, the “cut and sew” performed during heart transplantation results in a complete 
electrical isolation of the recipient’s posterior LA wall, pulmonary veins and venae cavae from the 
rest of the atria. This technique may therefore represent an in vivo, indirect model of a truly 
transmural lesion isolating the posterior wall and the venae cavae.  
The present observational, retrospective study on a large population of heart transplantation 
recipients aims to assess incidence, type and predictors of atrial arrhythmias during a long-term 
follow-up, in order to provide additional knowledge concerning the ideal atrial surgical lesion set to 






Consecutive patients undergone to heart transplantation at the Cardiac Surgery Division, “Città 
della Salute e della Scienza” Hospital, University of Turin, Italy, from 1990 to 2017, were 
retrospectively included. Inclusion criteria were: age over 18 years old, and orthotopic heart 
transplantation due to any underlying disease. Exclusion criteria were: death within the first month 
after transplant, and follow-up shorter than 6 months. The retrospective registry protocol was 
approved by the local Ethical Committee of the Hospital. 
 
Surgical technique  
Orthotopic heart transplantation was performed according to the bi-atrial technique in all patients, 
except one who received a heart transplant using the bi-caval technique. The bi-atrial technique was 
originally described by Lower and Shumway. Briefly, cardiectomy is performed leaving the two 
atrial cuffs with the orifices of the pulmonary veins and the venae cavae in the recipient. The graft 
is prepared creating two atrial cuffs. The LA is opened posteriorly connecting the orifices of the 
four pulmonary veins and trimming the tissue in excess. The right atrium is opened from the 
inferior vena cava towards the right atrial appendage. The two cuffs are then sutured to the 
recipient’s cuffs. Our surgical team started performing heart transplantation back in 1986 when the 
bi-atrial technique was the approach used by all the transplant centres worldwide. Since then, our 
surgical policy has never changed, due to a lack of documented benefit of the bicaval vs the original 
technique in terms of long-term survival. The experience with this type of procedure reduces the 
“theoretical” complications related with the suture of the two right atria. The risk of sino-atrial node 
injury is prevented by opening the donor’s right atrium from the inferior vena cava towards the 
atrial appendage leaving the node tissue far away from the suture line. The tricuspid annulus 
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distortion is avoided preserving enough tissue between the surgical suture and the atrio-ventricular 
groove.  
From an electrophysiological point of view, the two techniques are equivalent because the left atria 
suture is the same and the final ultimate result is that graft atria are completely isolated from the 
recipient’s atrial remnants.  
 
Clinical follow-up 
All patients included in the present analysis underwent routine clinical visit, ECG and blood tests at 
1, 2, 3, 6, 9, 12 months, then every 2 months up to the second year after transplant and every 6 
months, afterwards. In addition, right heart catheterization and endomyocardial biopsy were 
performed at 1, 2, 3, 6, 9 and 12 months; echocardiogram at 1, 3, 6, 12 months and then every year; 
cardiopulmonary exercise test and 24 hours Holter ECG every year and according to clinical 
demand. Coronary angiography was scheduled at one year after transplant and every 5 years 
thereafter. Additional investigations, such as longer duration monitoring or implantable loop 
recorder or additional right heart catheterizations were performed when needed according to 
symptoms and clinical presentation. All follow-up evaluations were performed at our Center. 
Baseline and follow-up clinical, echocardiographic, electrocardiographic, laboratory and 
hemodynamic characteristics of the enrolled patients were registered in a dedicated registry. All 
data were analysed by the Investigators according to current best practice. All available arrhythmic 
events, both ECGs and device interrogations, were re-analysed by two Investigators (M.A. and 







Sustained atrial arrhythmias were diagnosed by ECG, Holter monitoring or implanted devices, 
considering events lasting more than 2 minutes8. AF was defined by disorganized irregular (cycle 
variation beat-to-beat above 10%) atrial activity characterized by a rate over 300 beats per minute. 
Atrial flutter was defined by regular, organized atrial activity with a heart rate of 200 to 300 beats 
per minute. Atrial tachycardia was defined by regular organized atrial, non-sinusal activity with a 
heart rate of less than 200 beats per minute. As suggested by the recent guidelines8, in case of 
sustained arrhythmia detected by implanted devices, the heart rate and the stability (regular vs. 
irregular) of cycles were used as criteria to discriminate AF from atrial flutter. Arrhythmias were 
classified as paroxysmal in case of episodes lasting less than 7 days, interrupting spontaneously or 
by cardioversion, while persistent episodes were those lasting more than 7 days. 
Echocardiographic morphological and functional parameters were measured according to the 




Continuous variables, presented as means ± standard deviation (SD) or median [interquartile range] 
(IQR), were compared by ANOVA test or Student’s t-test after normal distribution was confirmed. 
Categorical variables, presented as counts and percentages, were compared in cross-tabulation 
tables by means of the Pearson chi-square test. Survivor curves were estimated using the Kaplan 
Meier method and equality of the survivor functions was tested by log-rank test. Multivariate 
analysis was performed through multinomial linear regression, including all items presenting a p-
value of less than 0.05 at univariate analysis. All tests of significance were two-tailed, and a p value 
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<0.05 was considered to indicate statistical significance. All analyses were performed by SPSS 21.0 
(IBM, USA) and STATA 12 (StataCorp, USA). 
 
Patient and Public Involvement 
This research was done without patient involvement.  Patients were not invited to comment on the 
study design and were not consulted to develop patient relevant outcomes or interpret the results. 





Overall, 364 patients undergoing heart transplantation at our Centre between 1990 and 2017 were 
enrolled. Among them 288 (79%) were males, and mean age at the time of transplant was 50.9±13 
years. All patients underwent heart transplantation with biatrial technique, apart from one patient 
suffering from a congenital heart disease that contra-indicated this technique and underwent bicaval 
technique. Three (0.8%) underwent a second heart transplant for severe primary graft dysfunction 
of the first graft.  
Baseline characteristics are reported in Table 1. The most common causes of heart transplantation 
were idiopathic dilated cardiomyopathy and ischaemic cardiomyopathy, affecting 165 (45.5%) and 
141 (38.8%) patients, respectively. Several comorbidities were present: arterial hypertension (234 
patients, 64.3%), diabetes (75, 20.7%), elevated BMI (202, 55.5%), history of previous stroke or 
TIA (37, 10%), peripheral artery disease (69, 19.0%), chronic obstructive pulmonary disease (22, 
6.0%) and obstructive sleep-apnoea syndrome (21, 5.8%). Forty-eight (13.2%) patients had a 
history of AF or other sustained atrial arrhythmias before heart transplantation.  
During a median follow-up of 120 (50-181) months, 108 (29.7%) patients died (time from 
transplant to death 113±7 months). Causes of death were: 24 (6.6%) advanced heart failure, 8 
(2.2%) sudden death and 20 (5.5%) non-cardiac deaths (malignancies, terminal renal failure or 
neurological events). In the remaining 56 (15.4%) cases the cause of death was unknown. Complete 
follow-up details are reported in Table 2. NYHA class was 1.3±0.7, and 240 (71.4%) patients were 
asymptomatic in NYHA class I. Left ventricular ejection fraction at echocardiography was 
57.0±10.2%. LA dilation was present in all patients, as per surgical technique, showing a mean LA 
indexed volume of 60.1±48.2 ml/m2. According to the latest classification of acute cellular rejection 
of the International Society for Heart and Lung Transplantation, at ventricular endocardial biopsy, 
89 patients presented acute cellular rejection ≥2R. Significant coronary disease was found in 22 
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(13.6%) patients. Concerning pharmacological therapy at follow-up, 210 (57.7%) were on diuretics, 
while only 2 (0.6%) assumed amiodarone as anti-arrhythmic medication (both due to ventricular 
arrhythmias). Of note, 54 (15%) patients had implanted devices for cardiac rhythm management. 
Three patients underwent catheter ablation, in all cases incisional atrial flutter was documented. 
Overall, 355 (97.5%) patients were in sinus rhythm. Only 9 patients suffered from persistent atrial 
arrhythmias: 8 (2.2%) for persistent atypical flutter, and one (0.3%) for persistent AF. Median time 
to develop persistent atrial arrhythmias was 90 (30-180) months. Paroxysmal sustained arrhythmias 
were registered in 42 (11.5%) patients, and in 13 of them the episodes were detected only at 
implantable device interrogation. All patients with paroxysmal arrhythmias presented an atypical 
atrial flutter, and no cases of paroxysmal AF were detected. The full description of atrial 
arrhythmias during follow-up is presented in Table 3 and in Supplemental Figure 1 in the Online 
Supplement.  
 
Predictors of atrial arrhythmias 
Univariate analysis was performed to assess the relation between clinical and instrumental 
parameters and the occurrence of atrial arrhythmias.  
Echocardiographic parameters, such as left ventricular end-diastolic diameter (p=0.025), Tei index 
(p=0.003), more than mild mitral and tricuspid regurgitation (p<0.001 and p=0.002), and 
haemodynamic parameters as systolic (p=0.007) and diastolic pulmonary pressure (p=0.001), 
capillary wedge pressure (p<0.001) and central venous pressure (p=0.004) related to higher 
incidence of any atrial arrhythmia (Table 1 and 2). Also, clinical features such as dyslipidaemia 
(p=0.040), weight (p=0.030) and previous pacemaker implantation (p=0.001) related to atrial 
arrhythmias occurrence. In contrast, LA volume was not related to atrial arrhythmias (p=0.969). 
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Notably, among the deceased patients, none developed persistent atrial arrhythmias during follow-
up, while 15 (13.8%) reported paroxysmal atrial flutter. Kaplan-Meier estimate of survival in the 
study cohort stratified by atrial arrhythmias occurrence is shown in Figure 1. No association was 
found between arrhythmic events and survival (p=0.176). Clinical parameters such as renal function 
(p<0.001), diabetes (p<0.001), anaemia (p<0.001) and symptoms of heart failure (NYHA class II or 
higher; p<0.001) related to higher risk of death. Consistently, diuretic treatment (p<0.001), left 
ventricular end-diastolic diameter (p<0.001) and ejection fraction (p<0.001) were found to be 
related to death. 
Multivariate analysis was performed to assess the independent effect of clinical and instrumental 
parameters on the incidence of atrial arrhythmias. None of the included parameters, however, 
showed significant independent correlation to the occurrence of any sustained atrial arrhythmia 






The aim of the present study was to assess long-term incidence of atrial arrhythmias and in 
particular of AF in a large population of heart transplanted patients. The main findings are: 
• a limited number of patients (2.2%) suffered from persistent incisional atypical flutter, as a 
consequence of surgical scars in the atria, while 11.5% patients suffered from paroxysmal 
episodes of atrial flutter; 
• persistent AF is extremely rare (one case); the presence of relevant comorbidities (justifying 
high mortality) do not relate to a proportionate incidence of persistent AF (as expected in a 
cohort of not transplanted patients with such comorbidities). 
AF is very common in patients suffering from structural heart disease, especially in those with 
enlarged LA10,11,12,13. In our study population of heart transplanted patients, despite a significant LA 
enlargement, there was a surprisingly low incidence of persistent AF. In fact, the significant 
incidence of organ rejection, along with the high prevalence of comorbidities such as renal 
dysfunction and diabetes, known to be related to AF occurrence, cardiovascular events and 
death14,15, related only to the latter (overall mortality around 30%) but not to the incidence of 
persistent AF, that remained very rare (0.3%/10 years of follow-up). It can be argued that heart 
transplanted patients indeed carry a “healthy” heart, received from the donor, however, 
comorbidities such as hypertension, renal dysfunction, diabetes, for example, are still present. This 
population is therefore a subset at a potentially high risk of developing AF, nevertheless the 
incidence of AF itself remains considerably low. As a matter of fact, the incidence of AF in 
similarly high-risk non-heart transplanted populations with the same prevalence of such 
comorbidities is reported to be significantly higher (over 20% lifelong at the age of 55)12,16 than the 




A plausible explanation for this low occurrence of AF is the preventive role exerted by the surgical 
lesion set in the atria, representing a complete, transmural electrical barrier. Moreover, the quantity 
of LA tissue of the graft is quite limited, indirectly demonstrating the role of atrial mass in the 
pathogenesis of AF.  
The incidence of AF in the long-term is indeed very low, despite a discrete number of patients 
experiencing a significant degree of chronic rejection, a condition that has specifically been related 
to AF occurrence and worse prognosis among heart transplanted patients17,18. This finding, in our 
opinion, strengthens the hypothesis of a protective role exerted by the surgical barriers of the 
transplant in preventing persistent AF in the long-term. Of note, our study was designed to assess 
the long-term incidence of AF, therefore patients presenting perioperative death, most of them 
caused by acute rejection, have not been included in the analysis; the results of this study therefore 
apply only to those patients presenting a favourable acute outcome of heart transplantation. 
 
Heart rhythm following atrial compartmentalization 
The discrepancy between clinical and cardiac conditions of the present population and the low 
incidence of persistent AF is noteworthy. Heart transplantation per se seems, in fact, to be 
protective against the occurrence of AF. More in details, the surgical technique connecting 
recipient’s and donor’s atria creates transmural electrical barriers that compartmentalize the native 
atria by isolating the pulmonary veins, which represents the cornerstone of AF ablation19, but also 
by isolating the entire LA posterior wall, resulting in a critical reduction of myocardial mass. As 
demonstrated by experimental models, in fact, critical mass is a key component, along with the 
presence of a trigger and autonomic nervous system modulation, for AF occurrence and most of all 
for persistent AF perpetuation20,21: it is therefore not surprising that complete electrical isolation of 
the pulmonary veins and the LA posterior walls protects transplanted hearts from developing 
persistent AF. Additionally, another relevant factor in preventing AF is indeed the denervation of 
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the transplanted heart: by interrupting the modulation of the autonomic nervous system towards the 
heart, the risk of developing AF is further reduced22.    
The incidence, although low, of atypical atrial flutter is not surprising. The substrate for this 
arrhythmia is completely different from AF and relies on the presence of multiple conduction 
corridors, usually in proximity of surgical scars that support reentry circuits23.  
On top of persistent arrhythmias, paroxysmal events were recorded, mainly by implanted devices, in 
about 10% of the population. At each device memory electrocardiogram analysis, events showed 
regular atrial activity, consistent with atrial flutter, and not AF. The presence of paroxysmal 
arrhythmias lasting few minutes, in fact, further supports the protective role of the atrial surgical 
scar by effectively and permanently modifying the substrate24,25, since even in the presence of an 
active paroxysmal trigger arrhythmias do not progress to persistent AF. 
Few other studies analysed the incidence of persistent AF among heart transplanted patients18,26-28, 
and these data have been recently merged in a meta-analysis, reporting a mean 10% incidence of 
AF over an heterogenic follow-up period spanning from 1 month to 11 years. In this analysis, AF 
occurrence was mostly related to patients’ age, renal failure, diabetes, post-transplant rejection and 
mitral regurgitation. However, most of the included studies did not discriminate AF from atrial 
flutter, that were often analysed together, and this easily explains the somewhat higher incidence of 
reported compared to our study. In the present study, as detailed in the Methods section, we 
carefully discriminated, based on guideline’s criteria, between AF, atrial flutter, and atrial 
tachycardia. Of note, in 3 (33%) of the 9 patients suffering persistent atrial arrhythmias the first 
clinical diagnosis of AF was modified to atrial flutter after focused revision of the ECGs. In 
addition, the majority of the paroxysmal events were misdiagnosed as AF and subsequently 
reclassified as flutter, after revision of the available tracings. In fact, considering both persistent and 
paroxysmal atrial arrhythmic events, and not only AF, also in the present population the incidence 




Current persistent AF ablation treatment 
Despite different approaches, current results of persistent AF CA remain suboptimal29. In fact, a 
clinical trial investigating the outcome of persistent AF ablation by linear lesions, the STAR-AF II, 
reported a similar incidence of recurrences with the sole isolation of the pulmonary veins30. 
However, it should be noted that in this trial lines were made empirically and often not validated by 
pacing manoeuvres. It is known from previous observational experiences, that obtaining real 
transmural, continuous and durable atrial lesion sets with the current ablation tools is difficult31, and 
this may represent the main determinant of the poor outcome of persistent AF transcatheter 
ablation. Conversely, the results of surgical AF ablation with linear lesions set are superior. In a 
long-term follow-up study, 10-year sinus rhythm maintenance was reported in 81% of long-
standing persistent AF and valvular heart disease patients25. This result, however, was obtained only 
in case the atrial linear lesions were validated at a following electrophysiological study; in fact, also 
after surgery alone, despite direct contact and visualization, atrial lines were not complete in 42% of 
the cases.  
Nowadays, the classical Cox-Maze “cut and sew” surgery is almost abandoned, due to its 
complexity, difficulty and procedure-related morbidity in unexperienced hands compared to recent 
open-heart and thoracoscopic techniques that employ radiofrequency or cryoenergy devices to 
perform pulmonary veins, posterior wall isolation and/or linear lesions19,32. However, the Cox-Maze 
biatrial “cut and sew” reported excellent results in terms of rhythm control4, and still ideally 
remains the most effective way to maintain long-term sinus rhythm. 
In this perspective, the atrial anastomoses during heart transplantation represent a true “cut and 
sew” of the tissue, and they represent an ideal atrial line lesions in vivo model, providing an indirect 
suggestion that performing truly continuous and transmural lesions isolating the posterior LA wall 




First, the aim of this study was to assess long-term incidence of atrial arrhythmias in patients 
undergone heart transplantation. In our analysis the patients who died within the first month after 
transplant were excluded, aiming to exclude perioperative mortality. This may represent a selection 
bias excluding the most fragile ones. Although comorbidities were quite common also in the 
analysed cohort of patients, the sickest patients may have been excluded. Second, the retrospective 
design of the present study does not allow a comparison with a control population. Heart 
transplanted patients have peculiar features mainly due to their long history of low cardiac output. 
This does not permit a real comparison that would be in any case difficult and, perhaps, misleading. 
Third, in addition to the surgical atrial compartmentalization, another mechanism potentially 
impacting AF incidence could be the denervation of graft. The specific impact of autonomic system 
imbalance has not been assessed. Additionally, follow-up based on Holter ECG can underestimate 
the real incidence of paroxysmal, asymptomatic arrhythmias; however, persistent episodes are 
surely more accurately diagnosed, and the prevalence is remarkably low. Finally, age of the donors 
and ischaemic time of the transplanted hearts, that can affect transplantation outcome, were not 
considered in this study. 
 
Conclusion 
Persistent atrial arrhythmias are rare among heart transplanted patients, despite significant LA 
enlargement and comorbidities resulting in significant morbidity and mortality. In particular, 
persistent AF is extremely rare, likely relating to the surgical biatrial technique, resulting in 
electrical isolation of the entire posterior LA wall and caval veins sinus. Atrial anastomosis 
represents an in vivo model of complete and transmural atrial compartmentalization, and our 
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findings support the need of achieving effective and transmural LA lines to further assess their role 







Table 1. Baseline clinical characteristics of the study population (364 patients). 








Age, years (SD)   50.9(13.0)    51.1(11.8) 49.9(12.8) 0.848 
Sex, n(%)       0.325 
Male 288(79.1) 245(78.3) 43(84.4)   
Female 76(20.9) 68(21.7) 8(15.7)   
BMI, kg/m2 (SD) 25.7(4.6) 25.6(4.7) 26.6(3.9) 0.178 
Weight (kg) 74.3(15.9) 73.6(16.3) 78.7(11.8) 0.030 
BMI >25. n(%) 202(55.5) 169(54.0) 33(64.7) 0.153 
Dyslipidemia. n(%) 173(48.2) 150(48.7) 23(45.1) 0.040 
Smoke history. n(%)       0.391 
Previous smoker 41(11.3) 36(11.5) 5(9.8)   
Current smoker 10(2.8) 10(3.2) 0(0)   
Stroke risk factors. n(%)         
Hypertension 234(64.3) 206(66.0) 28(54.9) 0.124 
Diabetes Mellitus 75(20.7) 67(21.8) 7(13.7) 0.593 
Peripheral artery diseases 69(19.0) 59(18.9) 10(19.6) 0.593 
Previous cerebrovascular event 37(10.2) 33(10.6) 4(7.8) 0.921 
Hyperthyroidism, n(%) 17(4.7) 13(3.5) 4(7.8) 0.578 
CKD grade (based on eGFR). n(%)       0.875  
Grade 1 56(15.5) 46(14.7) 10(20.4)  
Grade 2 89(24.6) 77(24.6) 12(24.5)  
Grade 3 141(39.0) 122(39.0) 19(38.8)  
Grade 4  50(13.8) 44(14.1) 6(12.2)  
Grade 5 or dialytic therapy       25(6.9) 23(7.3) 2(4.1)  
OSAS. n(%) 21(5.8) 20(6.4) 1(2.0) 0.452 
Genetic/autoimmune collagenopathies. n(%) 7(1.8) 7(2.2) 0(0) 0.884 
Structural heart disease. n(%)         
Idiopathic dilated CM 165(45.5) 146(46.8) 19(37.3) 0.288 
Ischemic CM 141(38.8) 122(39.0) 19(37.3) 0.802 
Post-myocarditis CM 16(4.4) 13(4.2) 3(5.9) 0.580 
Valvular heart disease 18(5.0) 13(4.2) 5(9.8) 0.086 
Congenital heart disease 5(1.4) 5(1.6) 0(0) 0.363 
Other CM 18(5.1) 13(4.2) 5(9.8)  
Mean CHA2DS2-VASc score. n(SD) 2.2(1.3) 2.2(1.4) 2.0(1.2) 0.176 
Pre-transplantation rhythm. n(%)       0.616 
Sinus rhythm 316(86.8) 274(87.5) 42(82.4)   
Persistent atrial flutter 3(0.8) 3(1.0) 0(0)   
Persistent atrial fibrillation 24(6.6) 19(6.1) 5(9.8)   
Paroxysmal atrial arrhythmias 21(5.8)       17(5.5) 4(7.9)   
 BMI: body mass index; CM: cardiomyopathy; CKD: chronic kidney disease; eGFR: estimated glomerular filtration 






Table 2. Clinical and instrumental parameters during follow-up. 
 









Follow up duration, months (median-IQR) 120(50-181) 115.0(78.0) 149.0(86.0) 0.005 
Deaths. n(%) 108(29.7) 93(29.7) 15(29.4) 0.965 
Re-transplantation. n(%) 3(0.8) 3(1.0) 0(0) 0.483 
Transplant rejection. n(%) 220(61.6)  194(86.6) 26(51.0) 0.678 
Maximum grade of rejection, n(%)       0.664 
0R 144(38.9)  120(38.3) 24(47.0)   
1R 131(35.3) 117(37.4) 14(27.44)   
≥2R 89(24.0) 76(24.3) 13(25.5)   
Mean NYHA class. n(SD) 1.3(0.7) 1.3(0.6) 1.2(0.7) 0.356 
NYHA class. n(%)      
1 240(71.4) 208(73.0) 37(72.5) 0.355  
2 64.0(19.0) 53(18.6) 11(21.6)   
3 23.0(6.8) 20(7.0) 3(5.9)   
4 1(0.3) 1(0.4)  0(0)   
Implanted pacemaker. n(%) 
 
54(15) 34(11) 20(39) 0.001 
Creatinine. mg/dl (SD) 1.9(1.3) 1.9(1.4) 1.9(1.3) 0.978 
Haemoglobin. mg/dl (SD) 12.6(2.0) 12.6(2.0) 12.8(1.9) 0.496 
Antiarrhhythmic drugs, n(%) 2(0.5) 2(0.6) 0(0) 0.682 
LVEDD. mm (SD) 46.5(7.0) 46.2(6.9) 48.6(7.1) 0.025 
LVEDV. ml (SD) 91.9(30.4) 91.3(29.9) 96.6(33.5) 0.381 
LA volume. ml/m2 (SD) 60.1(48.2) 60.22(52.8) 59.8(13.7) 0.969 
LVEF. % (SD)  57.0(10.2) 57.4(10.2) 54.7(10.0) 0.079 
Tei index. n (SD) 0.41(0.75) 0.34(0.18) 0.74(1.8) 0.003 
Valve regurgitation (more than mild)         
Mitral, n(%) 46(13) 32(10) 14(28) <0.001 
Tricuspid, n(%) 124(34) 98(31) 26(51) 0.002 
Coronary artery disease, n(%) 22(13.6) 16(12) 6(20.7) 0.225 
Cardiac catheterization       
PAPs. mmHg (SD)  29.9(8.4) 22.2(8.7) 33.4(9.1) 0.007 
PAPd. mmHg (SD) 13.0(6.3) 12.5(6.1) 16.2(6.8) 0.001 
PWCP. mmHg (SD) 12.3(6.0) 11.8(5.7) 15.4(7.1) <0.001 
Cardiac index. l/min/m2 (SD)  2.9(0.95) 2.9(0.98) 3.0(0.79) 0.365 
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LA: left atrium; LVEDD: left ventricular end diastolic diameter; LVEDV: left ventricular end diastolic volume; LVEF: 
left ventricuslar ejection fraction; PAPd: diastolic pulmonary artery pressure; PAPs: systolic pulmonary artery pressure; 
PCWP: pulmonary capillary wedge pressure. 
 
Table 3. Atrial arrhythmias detected during follow-up. 
 
Total  
[n = 364] 
Rhythm at the end of follow-up; n(%)   
Sinus rhythm 355(97.5) 
Persistent Atrial Flutter 8(2.2)  
Persistent Atrial Fibrillation 1(0.3) 
Paroxysmal atrial arrhytmias; n(%) 42(11.5) 
Arrhythmic events without ECG documentation  
(device interrogation consistent with atrial flutter) 
22(52.4) 
Atrial flutter, ECG documented  20(48.6) 
Mean episodes of paroxysmal atrial arrhythmia; n(SD) 1.3(0.75) 
Mean time from transplantion to first atrial arrhythmic event;  
months (median-IQR) 
90(30-180)  
Procedures after transplantation; n(%) 24(6.6) 
Cardioversion 21(5.8) 










Figure 1. Kaplan-Maier survival curves stratified by any atrial arrhythmias occurrence during 
follow-up (p=0.965). Analysis time is reported as months from transplantation. 
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